Drug intelligence / Profile preview

iPLTs-01

Development stage: Preclinical
Lead developer: HemaCell Biotechnology
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

iPLTs-01 is an induced pluripotent stem cell (iPSC)-derived platelet cell therapy being developed by HemaCell Therapeutics (Xue Ji Bio) for the treatment of thrombocytopenia. The therapy utilizes stem cell reprogramming and differentiation technologies to produce functional platelets *in vitro* from iPSCs. These manufactured platelets are intended to be administered to patients to replace or augment platelet function, addressing low platelet counts without the reliance on donor-derived blood products. iPLTs-01 is currently in the preclinical stage of development and is part of a pipeline that includes various blood type-specific and engineered platelet products.

Other names: iPLTs-01 (A-type)iPSC-derived platelet product

Beyond the preview

Go deeper on iPLTs-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iPLTs-01.

Explore the full profile